Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Ingmar Bruns Purchases 20,000 Shares

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Ingmar Bruns bought 20,000 shares of the company’s stock in a transaction on Thursday, February 6th. The shares were acquired at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the acquisition, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. This trade represents a 120.27 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $2.16 on Thursday. The stock’s 50 day moving average price is $2.69 and its 200 day moving average price is $3.14. The stock has a market cap of $153.92 million, a P/E ratio of -0.87 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.61 and a 12 month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of ZNTL. Verition Fund Management LLC increased its stake in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after buying an additional 951,500 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Zentalis Pharmaceuticals by 75.7% during the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company’s stock valued at $2,605,000 after acquiring an additional 370,511 shares during the period. GSA Capital Partners LLP raised its holdings in Zentalis Pharmaceuticals by 138.5% during the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after purchasing an additional 353,384 shares in the last quarter. Primecap Management Co. CA lifted its position in Zentalis Pharmaceuticals by 21.6% in the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after purchasing an additional 265,690 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Zentalis Pharmaceuticals by 126.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after purchasing an additional 127,868 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ZNTL shares. Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Guggenheim lowered their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. HC Wainwright cut their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Wedbush restated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, UBS Group dropped their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.